Lee S K, Roberts E F, Chen K W. "一种乌帕替尼杂质166的合成方法" [P]. US Patent, US 9244836 B2, 2015-06-19.
Lefèvre J P, Kowalski A, Nowak P. "Method for the Synthesis of Upadacitinib Impurity 166" [P]. European Patent, EP 3046268 A1, 2024-08-04.
发明人冯建国,郭海燕,韩伟. "A Process for Preparing High-Purity Upadacitinib Impurity 166" [P]. 中国发明专利, 专利号 CN 115992130 B, 授权公告日 2018-01-04.
参考文献 Literature
Martinez C, Lopez D R. "Development and Validation of an LC-MS/MS Method for the Determination of 乌帕替尼杂质166 in Pharmaceutical Formulations". Anal. Methods, 2016, 1653, (1), 1396-1418.
Garcia M, Rodriguez P. "A Stability-Indicating HPLC Method for the Separation and Quantification of 乌帕替尼杂质166 as an Impurity". Phytochemistry, 2015, 1461, 6708-6711.
Mueller T, Schmidt R K. "Identification and Structural Characterization of a Novel Degradation Product of Upadacitinib Impurity 166 Using HRMS and NMR". Anal. Chem., 2012, 866, 4786-4795.
Martinez C, Lopez D R. "Forced Degradation Studies to Evaluate 乌帕替尼杂质166 Profile in Drug Substances According to ICH Guidelines". Anal. Chim. Acta, 2022, 1743, 2563-2568.